All In Biotech

Drug Trial Radar · NCT07600151

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

A Clinical Phase I/II, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Sep 30, 2036

Study completion Dec 31, 2036

Sponsor

Lead sponsor
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie; Sanofi
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

Conditions

  • Myeloma Multiple
  • Myeloma

Interventions

  • EtentamigDrug

    Administered per the protocol

  • IsatuximabDrug

    Administered per the protocol

  • Bortezomib + Lenalidomide + DexamethasoneDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability (Phase I)Time frame: through induction treatment, on average 4 months
  2. MRD negativity (Phase II)Time frame: through consolidation phase completion, an average of 1 year
  3. PFSTime frame: up to 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.